Reading the offer · 22 company examples
FDA Letters About Vial Labels and Drug Claims
Two different questions behind one offer
A letter can challenge both the name pictured on a vial and what a seller says that vial contains or can do. These are separate questions: who made the compounded product, and whether the advertising suggests the same approval or evidence as a branded drug.
For a price comparison, fixing one question does not answer the other. Naming a pharmacy does not establish clinical equivalence, and changing a brand comparison does not identify the compounder. The company sections preserve both issues where FDA raised them.
The practical next step is to compare the actual preparation and the service being sold, rather than treating a familiar brand name or a branded-looking vial as a complete product description. A warning letter records the agency’s concerns at a stated date; it is not a current inspection of every prescription.
The Master Pharmaceuticals record shows why putting a brand name in parentheses beside a compounded ingredient can imply equivalence, even without an explicit comparison sentence.
An FDA warning letter is a public regulatory communication stating the agency's view. It is not a recall, a fine, a criminal charge, an injunction, or a finding that a company has broken the law.
This guide was organized in October 2026. Each company’s source-check date below is kept separately; the guide date does not mean its letter status was checked again.
24HrDoc
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA cited two things. The compounded products shown on the site "identify “24HrDoc” on the pictured label, suggesting 24HrDoc is the compounder of those drugs when in fact it is not." Separately it quoted two claims — "Same ingredients as: Ozempic and Wegovy" and "Same ingredients as: Mounjaro and Zepbound" — and concluded that "Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not." Both quoted lines say "ingredients", plural and unqualified, rather than the "same active ingredient" formula used elsewhere in this round of FDA letters.
What it means for the offer
Read the two quoted lines again and notice what is missing: the word "active". "Same ingredients as: Ozempic and Wegovy" is a claim about the whole formulation — everything in the vial — not about the one molecule the products share. That is a bigger promise than the sellers around it made, and it is the reason this letter exists. It also happens to be the promise a price comparison rests on, because if two products are identical in every respect then the only remaining variable is what you pay. FDA's answer does not touch the drug: it says a compounded product is not FDA-approved and this wording implied it had been evaluated when it had not. So the letter leaves the price alone and takes away the premise. If you are weighing a compounded course against a branded one, the difference between them is not nothing, and "same ingredients" was not a sound basis for treating it as nothing. This is a general-practice telehealth service, and the same reasoning applies to every product on the page, not only the GLP-1s.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [24HrDoc's website], in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.
The compounded semaglutide and tirzepatide products displayed on your website identify “24HrDoc” on the pictured label, suggesting 24HrDoc is the compounder of those drugs when in fact it is not.
Additionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website: “Same ingredients as: Ozempic and Wegovy” “Same ingredients as: Mounjaro and Zepbound”
Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
24HrDoc's website returned a live storefront on 2026-08-09 titled "24/7 Virtual Healthcare: Affordable Online Doctor Visits - 24hrdoc", with visits priced from $39.99 and per-product monthly pricing published on the home page, including a weight-loss product shown at a "First month" price of $149 against $249/month.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
altRx
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA cited two clipped fragments — "GLP-1s are clinically proven medications…." and "…clinically proven weight loss." — and, separately, that the pictured label identifies "altRx" as the compounder "when in fact it is not." Notably for a company that sells almost entirely on price, FDA quoted no pricing copy at all: the objection is that "clinically proven" represents the compounded products as "FDA-approved or otherwise evaluated for safety and effectiveness when they have not" been. The website FDA reviewed was documented under FDA Establishment Identifier 3044175714 in May 2026.
What it means for the offer
Worth stating plainly, because it would be easy to imply otherwise: FDA quoted no price copy from this company. The letter is about two fragments of the phrase "clinically proven" and about whose name is on the vial, and it makes no finding about whether the advertised price is accurate, sustainable or fair. That matters here more than elsewhere, because altRx sells hard on price — a headline monthly figure and a claim to be the cheapest program of its kind. Those are two separate questions, and this letter only answers the first. What it does tell you is that the evidence language wrapped around the price is not a regulatory credential, and that the company whose brand is on the label is not, on FDA's account, the one that compounded the contents. A genuinely low price is a reason to look closer at both, not a reason to skip the check.
Quoted passages and recorded context
Violations were identified and documented during a review of altRx’s website, [altRx's website], FDA Establishment Identifier (FEI) 3044175714, in May 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.
The compounded semaglutide and tirzepatide products displayed on your website identify “altRx” on the pictured label, suggesting altRx is the compounder of those drugs when in fact it is not.
“GLP-1s are clinically proven medications….”
“…clinically proven weight loss.”
Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
altRx's website returned a live storefront when we checked in August 2026, leading with a summer promotion, a headline monthly price for its GLP-1 and GLP-1 + GIP programs and a claim to be the most affordable such program. We did not review every page on the site.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Letter issued · Status last checked · Active at that check
What FDA cited
FDA cited a claim that runs the comparison backwards — "Ozempic, Mounjaro, and Wegovy contain the same active ingredients as our compounded versions (semaglutide and tirzepatide)" — putting the brands in the subject position so that the compounded product becomes the reference point rather than the copy. It also cited "All our treatments use FDA-approved active ingredients…." and noted the pictured label identifies "amie" as the compounder when it is not. FDA said the claims represent the products as "FDA-approved or otherwise evaluated for safety and effectiveness when they have not" been.
What it means for the offer
Two things here are worth separating. The first is the sentence FDA quoted, which is built the wrong way round: instead of saying the compounded vial matches the brand, it says the brands match the compounded vial. The grammar quietly promotes the compounded product to the standard against which Ozempic, Mounjaro and Wegovy are measured — and the approval still belongs to the brands. The second is what we found when we looked. The GLP-1 catalog FDA reviewed in March 2026 was not on the homepage in August 2026; the company was selling something else entirely. That is a normal thing for a young telehealth brand to do and it is not a shutdown, but it does affect how you use a price you saw quoted somewhere. Catalogs in this market move fast, and a listed GLP-1 price is worth re-checking on the seller's own site before you treat it as current.
Quoted passages and recorded context
Violations were identified and documented during a review of Amie Health, Inc.’s website, [Amie's website], FDA Establishment Identifier (FEI) 3044000672, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.
The compounded semaglutide and tirzepatide products displayed on your website identify “amie” on the pictured label, suggesting Amie is the compounder of those drugs when in fact it is not.
“Ozempic, Mounjaro, and Wegovy contain the same active ingredients as our compounded versions (semaglutide and tirzepatide).”
“All our treatments use FDA-approved active ingredients….”
Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
Amie's website returned a live storefront when we checked in August 2026, but selling an on-demand libido formula for women with clinician review and a refund-if-not-approved promise. We saw no GLP-1, semaglutide or tirzepatide product on the homepage at that check. We did not review every page or complete an intake, so this is not confirmation that the products named in the letter were withdrawn.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Amp Health
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA cited the pictured label first: the compounded products on the site "identify “Amp Health” on the pictured label, suggesting Amp Health is the compounder of those drugs when in fact it is not." It then quoted two marketing claims — "The same active ingredient in Wegovy®*, Ozempic®*, and Saxenda®*" and "Featuring the same active ingredient found in Mounjaro®* and Zepbound®*." — reproducing the asterisk the site had attached to each brand name, and held that "Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not."
What it means for the offer
The asterisks are the whole story here. Somebody at this company had already decided the brand names needed a footnote — that is what an asterisk after Wegovy®* is for — and FDA quoted the asterisks and cited the copy anyway. The lesson for a reader is not that disclaimers are worthless; it is that a disclaimer attached to a comparison does not convert the comparison into an accurate one. If the sentence you are reading says a compounded product carries the same active ingredient as three branded drugs, the small print at the bottom of the page is not what determines whether that is a fair thing to tell you. There is a second, more practical point. This letter went to Dripgym Mobile Parent, LLC — a name that appears nowhere on the storefront and shares nothing with the domain. If you were trying to look up who you were buying from, the warning letter was the document that connected the three. Neither finding concerns the medicine's quality; both concern how much you could learn from the page before paying.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Amp Health's website], in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.
The compounded semaglutide and tirzepatide products displayed on your website identify “Amp Health” on the pictured label, suggesting Amp Health is the compounder of those drugs when in fact it is not.
Additionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website: “The same active ingredient in Wegovy®*, Ozempic®*, and Saxenda®*” “Featuring the same active ingredient found in Mounjaro®* and Zepbound®*.”
Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, these claims are false or misleading and your products are therefore misbranded
Amp Health's website was up in August 2026 but showed only a holding page titled "Maintenance Page - AmpHealth", reading "Website is under maintenance. We are doing some maintenance on our website to improve your experience", alongside promotional copy ("Get Your First Month of Weight Loss Medication for Free"). No catalog, price or checkout was reachable. A maintenance page can come before a relaunch, so we record this as unknown rather than closed.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
BluefitMD
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA made two findings in one letter. First the label: the products displayed on the site "identify “BluefitMD” on the pictured label, suggesting BluefitMD is the compounder of those drugs when in fact it is not." Then, introduced by the word "Additionally", the copy: "Compounded Semaglutide (the same active ingredient as Ozempic® and Wegovy®)" and "Compounded Tirzepatide (the same active ingredient as Mounjaro® & Zepbound®)". FDA's conclusion on the second was that "Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not." No other letter in this collection contains both.
What it means for the offer
Read the two findings together and they answer each other. The copy said the vial holds the same active ingredient as Ozempic; the photograph of that vial said BluefitMD made it — and FDA's position is that BluefitMD did not. So the page told a shopper both what is inside and who put it there, and the second answer was wrong, which is a reason to be careful with the first. That pairing is what makes this the most instructive letter in the collection: a name on a label is not a marketing claim, it is an answer to "who is accountable", and it was answered by a company that, on FDA's account, was the seller rather than the compounder. The site's advertised price today is the other half of the lesson — "As low as $75/mo", with the asterisk resolving to "*With a 12-month package". A headline rate that requires twelve months of commitment is a different product from a monthly one, and the figure a reader remembers is the one before the asterisk. None of this is a finding about the drugs themselves; FDA made no claim here about quality, contents or manufacturing, and the letter has not been closed out.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [BluefitMD's website], in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.
The compounded semaglutide and tirzepatide products displayed on your website identify “BluefitMD” on the pictured label, suggesting BluefitMD is the compounder of those drugs when in fact it is not.
Additionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website:
“Compounded Semaglutide (the same active ingredient as Ozempic® and Wegovy®)”
“Compounded Tirzepatide (the same active ingredient as Mounjaro® & Zepbound®)”
Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
BluefitMD's website returned a live storefront on 2026-08-09 advertising "Personalized GLP-1 Treatments As low as $75/mo*" with the footnote "*With a 12-month package", alongside testosterone, NAD+, methylene blue and sermorelin categories and compounded semaglutide and tirzepatide product pages. That is a check of whether the site is up and what it advertises; it is not a check of anything the letter alleges.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Deluxe IV and Aesthetics
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA made a label finding and a claim finding. The products "identify “Deluxe IV and Aesthetics” on the pictured label, suggesting Deluxe IV and Aesthetics is the compounder of those drugs when in fact it is not". The three quoted claims then reach for five brands, and two of them carry a footnote asterisk on the trademark symbol: "Same active pharmaceutical ingredient in Ozempic® and Mounjaro®.", "Semaglutide is the active pharmaceutical ingredient in Ozempic®*, Rybelsus®*, and Wegovy®*" and "Tirzepatide is the active pharmaceutical ingredient in Mounjaro®* and Zepbound®*." FDA held these "imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not."
What it means for the offer
The asterisks are the tell. Someone at this business knew the trademarks belonged to other companies, marked them, and pointed the reader at a disclaimer — and FDA cited the claims all the same. That is the single most useful thing this letter teaches, because asterisked brand names are everywhere in compounded GLP-1 marketing and they are widely read as a sign that a seller is being careful. What the footnote can do is disclaim ownership of a trademark. What it cannot do is unsay the sentence it is attached to: "Semaglutide is the active pharmaceutical ingredient in Ozempic®*, Rybelsus®*, and Wegovy®*" is a true statement about those three approved products, placed on a page selling a fourth thing that is none of them, and the implication survives any small print underneath. Read the two findings together and the pattern is complete — the label said the seller made the drug, and the copy said the drug was what the brands are. Neither of those is about safety, and FDA alleges nothing about the product's quality. The practical version: an asterisk beside a brand name tells you the seller has thought about trademarks, not that the comparison beneath it holds. The domain on the letter is no longer registered.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Deluxe IV and Aesthetics' website], in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products. As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].
The compounded semaglutide and tirzepatide products displayed on your website identify “Deluxe IV and Aesthetics” on the pictured label, suggesting Deluxe IV and Aesthetics is the compounder of those drugs when in fact it is not. Accordingly, the representations on your website that Deluxe IV and Aesthetics is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
“Semaglutide is the active pharmaceutical ingredient in Ozempic®*, Rybelsus®*, and Wegovy®*”
“Tirzepatide is the active pharmaceutical ingredient in Mounjaro®* and Zepbound®*.”
Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
Deluxe IV and Aesthetics' website did not exist in August 2026: the address led nowhere, and the domain registry showed the name is no longer registered to anyone. An unregistered web address is not proof a clinic has closed — the Las Vegas practice may operate under another name — so this is recorded as unknown.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Fifty 410
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA made a label finding and a claim finding. The products "identify “Fifty 410” on the pictured label, suggesting Fifty 410 is the compounder of those drugs when in fact it is not", so the representations that the company compounded them "are false or misleading". The only claim FDA then quoted is three words long and names no brand and no drug: "clinically proven ingredients". FDA held that even this "implies that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not" — the shortest cited claim in this dataset, and the only one that borrows nothing from a trademark.
What it means for the offer
Strip out every brand name and you still have a claim. That is what this letter demonstrates, and it is why it is the most useful one in the set for reading marketing copy generally. "Clinically proven ingredients" mentions no product, makes no comparison and could be written by someone deliberately avoiding trademarks — and FDA held it implies the products "have been FDA-approved or otherwise evaluated for safety and effectiveness". The reason is that clinical proof is a property of a studied product at a studied dose, not of a substance in the abstract. Semaglutide has been proven in trials; a compounded semaglutide preparation of some strength, from some facility, has not been in those trials, and inheriting the evidence is the same borrowing as inheriting the name, just done without the name. Pair it with the other finding — the vial carried the seller's name, not the compounder's — and both halves of the provenance question come out wrong: what made this, and what is it proven to do. Neither finding says anything about whether the medication is safe or well made. The site is trading today at a headline of $199 a month, and "clinically proven" no longer appears on its front page.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Fifty 410's website], in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products. As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].
The compounded semaglutide and tirzepatide products displayed on your website identify “Fifty 410” on the pictured label, suggesting Fifty 410 is the compounder of those drugs when in fact it is not. Accordingly, the representations on your website that Fifty 410 is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
Additionally, the following claim concerning compounded semaglutide and tirzepatide products appears on your website:
“clinically proven ingredients”
Compounded drug products are not FDA-approved. Your claim implies that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, this claim is false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
Fifty 410's website was a live storefront in August 2026, titled "GLP-1 Weight Loss Medication Online | Fifty 410", advertising "100k+ customers", listing compounded semaglutide and tirzepatide "Starting at $199 /month" alongside hair, NAD+ and sermorelin products, with a working sign-up — an operating seller. The phrase "clinically proven" did not appear on the homepage when we looked.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
FITISH
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA quoted this company's product copy exactly as written, typo included, and marked it: "Semaglutide is the active ingredient in ozempic" [sic] — the bracketed note is FDA's own. The second cited claim is the tidier "Tirzepatide is the active ingredient in Mounjaro® and Zepbound®". Neither is a headline or a slogan; both are ordinary descriptive lines. FDA said they represent the compounded products as "FDA-approved or otherwise evaluated for safety and effectiveness when they have not" been, and separately that the pictured label identifies "FITISH" as the compounder when it is not.
What it means for the offer
The [sic] is FDA's, and it tells you how these letters are built. Nobody rewrote the sentence, softened it or summarized it — an agency lawyer copied a lowercase line out of a product description and put it in a federal letter with a note that the error was the company's. That is worth knowing before you read any page in this collection, because it sets the scale. These are not investigations into how medicines were made. They are readings of website copy, sometimes a slogan, sometimes a fragment, occasionally a typo. A letter can therefore land on a company that is doing very little wrong in ordinary terms, and a company with no letter is not thereby endorsed — it may simply have written more careful sentences. Use the letter for what it reliably shows: on the date FDA looked, this page claimed an approval the compounded product did not have. Judge the price on its own.
Quoted passages and recorded context
Violations were identified and documented during a review of FITISH’s website, [FITISH's website], FDA Establishment Identifier (FEI) 3044018836, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.
The compounded semaglutide and tirzepatide products displayed on your website identify “FITISH” on the pictured label, suggesting FITISH is the compounder of those drugs when in fact it is not.
“Semaglutide is the active ingredient in ozempic” [sic]
“Tirzepatide is the active ingredient in Mounjaro® and Zepbound®”
Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
FITISH's website returned a live storefront when we checked in August 2026, selling compounded semaglutide and tirzepatide, oral tirzepatide tablets, GLP-1 microdosing, NAD+ and sermorelin alongside a beauty and merchandise range. We did not review every page on the site.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
FitRx
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
The claims FDA cited here are parentheticals inside shipping copy rather than headlines: "semaglutide (active ingredient in Wegovy) or tirzepatide (active ingredient in Zepbound)" and "we can ship semaglutide, the main active ingredient in Wegovy and Ozempic, or Tirzepatide, the main active ingredient in Zepbound and Mounjaro". FDA said they imply the products "have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not," and separately that the pictured label identifies "FitRx" as the compounder when it is not. What sets this letter apart is the recipient: FitRX, LLC had already received a letter five months earlier under a different trading name.
What it means for the offer
The interesting fact about this letter is not the copy — it is the letterhead. FitRX, LLC is named in FDA's database three separate times across the three telehealth waves, once as Zealthy in September 2025, once as FitRx here, and once as AM RX in June 2026. One company, three storefronts, three letters. That is worth knowing when you are shopping, because a comparison table treats brands as competitors: you can line up three prices, feel you have surveyed the market, and be looking at one operator throughout. The letters themselves remain narrow — cited marketing phrases, no finding about the medication, no shutdown, and receiving several is not itself evidence of anything worse than operating several sites. But the brand names are not independent data points, and if you are checking a company's regulatory record, the name on the homepage is not always the name FDA wrote to.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [FitRx's website], in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.
The compounded semaglutide and tirzepatide products displayed on your website identify “FitRx” on the pictured label, suggesting FitRx is the compounder of those drugs when in fact it is not.
“we can ship semaglutide, the main active ingredient in Wegovy and Ozempic, or Tirzepatide, the main active ingredient in Zepbound and Mounjaro”
Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
FitRx's website returned a live storefront when we checked in August 2026, covering weight loss, hair loss, birth control, mental health, skincare, enclomiphene and erectile dysfunction. We did not review every page on the site.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Genesis
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA made two findings about Genesis' website. The pictured products "identify “Genesis” on the pictured label, suggesting Genesis is the compounder of those drugs when in fact it is not." It then quoted two claims — "Contains the same active ingredient as Ozempic® and Wegovy®" and "Same active ingredient as Mounjaro®" — and wrote that compounded drug products are not FDA-approved and the claims "imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not."
What it means for the offer
The private-label finding is the one that changes how you read a price. A vial with the seller's own name on it invites you to think you are buying from them — that they made it, that the price is their cost plus their margin, that quality questions have one address. FDA says the seller is not the compounder. So the name on the label is branding applied to someone else's product, and the actual manufacturer is not disclosed to you at the point where you are deciding what the medicine is worth. That is not a safety finding and it is not unusual in this market; nearly every letter in this collection contains the same observation. What it means practically is that two sellers at very different prices can be shipping vials from the same facility with different names printed on them, and nothing on either page will tell you.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Genesis' website], in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.
The compounded semaglutide and tirzepatide products displayed on your website identify “Genesis” on the pictured label, suggesting Genesis is the compounder of those drugs when in fact it is not.
Additionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website: “Contains the same active ingredient as Ozempic® and Wegovy®” “Same active ingredient as Mounjaro®”
Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
Genesis' website returned a live storefront on 2026-08-09, titled "Genesis Health | Lose Weight with Proven GLP-1 Medications Personalized Tirzepatide & Semaglutide doses", with published monthly prices and the same Boynton Beach corporate details the letter gives.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Join Josie
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
Read literally, the cited sentences are accurate: "The same active ingredient found in the FDA-approved brand Wegovy®." and "The same active ingredient found in the FDA-approved brand Zepbound®." Wegovy and Zepbound are approved, and those are their active ingredients. FDA cited them because the approval is fixed to the brand named in the sentence while the product on sale is compounded — so the claims imply the compounded products "have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not." FDA also noted the pictured label identifies "Join Josie" as the compounder when it is not.
What it means for the offer
This is the letter that shows a claim can be true sentence-by-sentence and still mislead. Every fact in "the same active ingredient found in the FDA-approved brand Wegovy®" checks out — and the approval in it belongs to Wegovy, not to the vial being sold. The registered symbol reinforces the effect, because a trademark signals a real, regulated product standing behind the words. For a reader weighing a menopause-care subscription against a brand prescription, the difference matters more than usual: these decisions are often made alongside hormone therapy, where "approved" and "compounded" also sit side by side and are also easy to blur. Nothing in the letter suggests the medication is ineffective or that the company handled anyone's care poorly. It says the credential in the sentence belongs to a different product than the one in the cart.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Join Josie's website], in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.
“The same active ingredient found in the FDA-approved brand Wegovy®.”
“The same active ingredient found in the FDA-approved brand Zepbound®.”
The compounded semaglutide and tirzepatide products displayed on your website identify “Join Josie” on the pictured label, suggesting Join Josie is the compounder of those drugs when in fact it is not.
Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
Join Josie's website returned a live storefront when we checked in August 2026, offering hormone replacement therapy, weight management and weight maintenance for perimenopause and menopause, and citing a membership figure. We did not review every page on the site.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Levity
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA cited two claims from Levity's website. The first is the familiar ingredient comparison, "The same ingredient as Ozempic® + Wegovy®". The second makes no ingredient argument at all — "The power of Saxenda®" — attaching the brand and its trademark symbol to a compounded liraglutide product. FDA separately wrote that the products pictured on the site "identify 'Levity' on the pictured label, suggesting Levity is the compounder of those drugs when in fact it is not," and concluded that the claims imply the products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
What it means for the offer
Liraglutide is the reason this letter reads differently from the rest. It is the older daily GLP-1, and a compounded version of it is usually the cheapest injectable on a menu — which is exactly why the phrase FDA objected to matters. "The power of Saxenda®" does not say the product contains the same ingredient, does not cite a trial, and does not compare a price; it simply transfers a brand's reputation onto a cheaper item beside it. There is no factual claim there to check, which is what makes it effective and what FDA said makes it misleading. When a low-priced option is sold on a brand's borrowed reputation rather than on its own description, the price is the only thing on the page you can actually verify.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Levity's website], in December 2025, and has observed that your website offers compounded drug products, including semaglutide and liraglutide drug products.
The compounded semaglutide and liraglutide products displayed on your website identify “Levity” on the pictured label, suggesting Levity is the compounder of those drugs when in fact it is not.
“The same ingredient as Ozempic® + Wegovy®” “The power of Saxenda®”
Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
Levity's website returned a live storefront when we checked in August 2026, advertising a first month at a discounted rate with a published ongoing monthly price and listing branded Ozempic, Wegovy and Mounjaro as in stock.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
NativeMed
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
Alone among these letters, FDA described a logo rather than a name: the compounded tirzepatide products "feature NativeMed's logo on the pictured label, suggesting NativeMed is the compounder of those drugs when in fact it is not." The only marketing phrase cited is a single line — "The same active ingredient in Ozempic® and Wegovy®" — which FDA said represents that the products "have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not."
What it means for the offer
This letter is a small but clarifying variation. A brand mark is not a word, and you might assume the rule about names on drug labels turns on printed text — FDA's wording here says otherwise, treating a logo as making the same representation. The underlying idea is consistent across every private-label letter in this dataset: whatever a vial's packaging says about who made it is a claim, and if the company on the front did not compound the contents, the impression is misleading. What follows for a shopper is worth carrying to every listing you compare. Branded packaging is a design decision made by the seller, so two vials with different logos on them can come from the same pharmacy, and two vials with the same price can come from different ones. If you want to know what you are buying, the question is which facility filled it, and that is exactly what FDA asked this company to disclose.
Quoted passages and recorded context
Violations were identified and documented during a review of NativeMed’s website, [NativeMed's website], FDA Establishment Identifier (FEI) 3044024130, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.
The compounded tirzepatide products displayed on your website feature NativeMed’s logo on the pictured label, suggesting NativeMed is the compounder of those drugs when in fact it is not.
“The same active ingredient in Ozempic® and Wegovy®”
Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
NativeMed's website returned a live storefront when we checked in August 2026, running a seasonal promotion and showing semaglutide and tirzepatide as in stock. We did not review every page on the site.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Newman Clinic
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA made a label finding and a claim finding. The products "identify “Newman Clinic” on the pictured label, suggesting Newman Clinic is the compounder of those drugs when in fact it is not", so the representations that the clinic compounded them "are false or misleading". The claims FDA then quoted are the briefest in this dataset — two verbless fragments, "Same Ingredient as Ozempic® and Wegovy®" and "Same Ingredient as Mounjaro® and Zepbound®" — which FDA held "imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not."
What it means for the offer
Two things here are worth a reader's attention, and the first is how little the claim had to say. "Same Ingredient as Ozempic® and Wegovy®" is five words with no verb, no promise and no mention of approval — and FDA still held that it implies the compounded product has been evaluated for safety and effectiveness. That is a useful calibration when comparing pages: a claim does not have to be a sentence, or overstated, or even complete to carry the implication FDA objects to. The registered trademark symbols do part of the work, borrowing the weight of the brands they belong to. The second is that this letter went to a named clinician at her own practice, not to a marketing company. It is a reminder that these findings are about published copy rather than about clinical judgment, and that a small telehealth practice run by an identifiable provider is subject to the same standard as a venture-funded platform. Nothing in the letter concerns the safety of the medication or the quality of care — it concerns whose name was on the vial and what two short lines of website copy told a reader.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Newman Clinic's website], in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products. As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].
The compounded semaglutide and tirzepatide products displayed on your website identify “Newman Clinic” on the pictured label, suggesting Newman Clinic is the compounder of those drugs when in fact it is not. Accordingly, the representations on your website that Newman Clinic is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
Additionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website: “Same Ingredient as Ozempic® and Wegovy®” “Same Ingredient as Mounjaro® and Zepbound®”
Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
Newman Clinic's website returned a live site on 2026-08-09 titled "Weight Loss, Hormone Therapy, & Concierge Medicine I Newman Clinic", listing semaglutide, tirzepatide and phentermine under weight-loss medications, stating service in AZ, CA, HI, OH and TX, and running a grand-opening referral promotion — an operating practice.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
NewSelf
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
Alongside the private-label finding — products picturing a label that identifies "NewSelf" as the compounder when it is not — FDA quoted four items from NewSelf's website. Two are ordinary comparisons, "Same active ingredient as Ozempic® & Wegovy®" and "Same active ingredient as Mounjaro® & Zepbound®". The other two are FAQ headings that ask rather than assert: "What is the FDA-approved use of Wegovy?" and "What is the FDA-approved use of Zepbound?" FDA wrote that compounded drug products are not FDA-approved and that the claims "imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not."
What it means for the offer
The two FAQ questions are the interesting part, because on their face they are the responsible thing to do. "What is the FDA-approved use of Wegovy?" is a true question about a real approved drug, and answering it accurately is a service. FDA's point is about placement, not accuracy: put that question on a page selling a compounded product and the approval it describes drifts across to the thing being sold, without anyone having claimed it. That is a hard defect to shop around, because it does not live in any one sentence you could fact-check — it lives in what a page is about versus what it discusses. When you are weighing this seller's price against another's, the honest read is that nothing here says the medicine is bad or the price is wrong; it says the FDA-approval language surrounding the offer belongs to a different product than the one in the cart.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [NewSelf's website], in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.
The compounded semaglutide and tirzepatide products displayed on your website identify “NewSelf” on the pictured label, suggesting NewSelf is the compounder of those drugs when in fact it is not.
Additionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website: “Same active ingredient as Ozempic® & Wegovy®” “Same active ingredient as Mounjaro® & Zepbound®” “What is the FDA-approved use of Wegovy?” “What is the FDA-approved use of Zepbound?”
Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
NewSelf's website returned a live storefront on 2026-08-09, titled "NewSelf Weight Loss Protocol", with a published price ladder and a working cart, so the site was transacting at that check.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
PharmaZee
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA cited the same adjective twice over, in two forms — "clinically proven medications" and "proven prescription medications" — alongside "Same active ingredient as Ozempic® and Wegovy®". Neither "proven" phrase names a study, an endpoint or a product. FDA said the claims imply the compounded products "have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not," and separately that the pictured label identifies "PharmaZee" as the compounder when it is not.
What it means for the offer
"Proven" is a strong word carrying no information, which is why it turns up twice here. A proven medication implies someone ran a study, on something, and reached a result — but the phrase as quoted names no trial, no endpoint and no product, so there is nothing a reader can check. FDA's objection is that the word transfers the credibility of the approved brand's evidence onto a compounded preparation that was not part of it. Notice what is absent from this letter: no price claim, no dosing claim, no safety finding, and no suggestion the medication does not work. For a shopper the practical move is to treat "proven" and "clinically proven" as design elements rather than data. If a page wants to convince you on evidence, it can name the trial; if it only offers the adjective, price the product as what it is — a compounded preparation — and judge the cost against compounded competitors rather than against the brand.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [PharmaZee's website], in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.
“clinically proven medications”
“proven prescription medications”
“Same active ingredient as Ozempic® and Wegovy®”
Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
PharmaZee's website returned a live storefront when we checked in August 2026, covering GLP-1 weight loss plus longevity, hair-loss, anti-aging and sexual-health lines with discreet delivery. We did not review every page on the site.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Refills Health
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
Both cited phrases are hedged, and FDA cited them anyway. One is the bare fragment "clinically proven"; the other, "the same active ingredient found in certain FDA approved treatments", inserts the qualifier "certain" — narrowing which approved treatments are meant without changing what the sentence implies about the compounded vial. FDA said such claims imply the products "have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not." The agency also noted the pictured label identifies "Refills Health" as the compounder, "when in fact it is not."
What it means for the offer
The word "certain" is the tell, and it is worth understanding why it did not help. Adding a qualifier makes a sentence more accurate about the brands being referenced while leaving untouched the thing FDA cared about: what the reader concludes about the vial being sold. That is the general shape of these letters — the agency is not grading the sentence for technical truth, it is asking what an ordinary shopper takes away. Nothing here concerns price, and nothing concerns whether the medication works. So the practical use of this letter is narrow. It tells you that careful wording on a product page is not the same as a regulatory credential, and that when you are comparing this company's number against a brand's, you are comparing a compounded product against an approved one regardless of how precisely the page is written.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Refills Health's website], in December 2025, and has observed that your website offers compounded drug products, including semaglutide drug products.
The compounded semaglutide products displayed on your website identify “Refills Health” on the pictured label, suggesting Refills Health is the compounder of those drugs when in fact it is not.
Additionally, the following claims concerning compounded semaglutide products appear on your website: “clinically proven”
“the same active ingredient found in certain FDA approved treatments”
Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
Refills Health's website returned a live storefront when we checked in August 2026, with personalized GLP-1 and GIP+GLP-1 products alongside intimacy, hair-growth and daily-health lines. We did not review every page on the site.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
RoenRx
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
The sentence FDA quoted here — "Get affordable semaglutide (main ingredient in Ozempic® & Wegovy®) at an affordable price." — is word-for-word identical to a sentence FDA quoted the same day from a different company, AM RX. A second cited line matches too, and a third differs only in the brand name. FDA cited the copy because it represents the compounded product as "FDA-approved or otherwise evaluated for safety and effectiveness" when it has not been, and separately noted the pictured label identifies "RoenRx" as the compounder when it is not.
What it means for the offer
The most useful thing on this page is something you can check yourself in about a minute: open this letter and the AM RX letter side by side, both dated June 2026, and read the quoted claims. One sentence is identical, down to the odd repetition of "affordable" twice in twelve words. Another differs only by the company name. These are two separately named businesses that were writing the same product page. Nothing in either letter says who wrote it first or whether the two are connected, and we are not asserting that they are — but it does undercut the idea that comparing several telehealth brands means comparing several independent offers. Some of these storefronts are assembled from shared parts. When two listings quote you similar prices in similar words, the sensible next question is which pharmacy actually fills each one, which is precisely what FDA asked both companies to disclose.
Quoted passages and recorded context
Violations were identified and documented during a review of RoenRx’s website, [RoenRx's website], FDA Establishment Identifier (FEI) 3044022969, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide products.
The compounded semaglutide products displayed on your website identify “RoenRx” on the pictured label, suggesting RoenRx is the compounder of those drugs when in fact it is not.
“RoenRx also offers semaglutide, the active ingredient in Wegovy® and Ozempic®….”
“Get affordable semaglutide (main ingredient in Ozempic® & Wegovy®) at an affordable price.”
Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
RoenRx's website returned a live storefront when we checked in August 2026, covering weight loss, hair, sexual health, birth control, mental health and skincare. We did not review every page on the site.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Thrivelab
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA cited three short lines from Thrivelab's website — "Same active ingredient as Ozempic®", "Same active ingredient as Wegovy and Ozempic" and "clinically proven to work" — and wrote that the claims "represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not." It also found that the pictured labels identify "thrivelab" as the compounder when it is not. The letter is addressed not to the company but to its founder and chief executive by name and title.
What it means for the offer
It is tempting to read the personal address as a sign FDA took this case more seriously than the others, and there is nothing in the letter that supports that reading — the findings are the mildest kind in the collection, two same-ingredient lines and a four-word efficacy phrase. Who a letter is addressed to is a clerical fact, not a measure of severity, and treating it as one is precisely the mistake these pages exist to prevent. What is worth carrying into a price comparison here is smaller and specific: the compounded semaglutide sits in a catalog with hormone therapy, coaching and primary care, sold partly on insurance savings, and FDA's finding is that the vial's branding identifies a seller rather than a compounder. The cost of a bundle tells you nothing about who made the one prescription drug inside it.
Quoted passages and recorded context
Violations were identified and documented during a review of Thrivelab's website […], FDA Establishment Identifier (FEI) 3043997633, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide products.
1. The compounded semaglutide products displayed on your website identify “thrivelab” on the pictured label, suggesting Thrivelab is the compounder of those drugs when in fact it is not.
“Same active ingredient as Ozempic®” “Same active ingredient as Wegovy and Ozempic” “clinically proven to work”
Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
Thrivelab's website returned a live storefront when we checked in August 2026, still listing a semaglutide weight-loss program alongside hormone therapy, peptides, nutrition coaching and virtual primary care, and promoting insurance-based cost reduction.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Zappy
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA cited product listings on Zappy's website that named each compounded drug as the "Active Pharmaceutical Ingredient" in a brand — Wegovy, Saxenda, Zepbound — and then, in the same line, pointed the reader to FDA's own material about that brand: "See Wegovy FDA Information". It also quoted "a proven medication" and "Clinically studied and shown to deliver powerful results when combined with healthy habits." FDA said these claims imply the compounded products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not, and separately that the pictured labels identify "Zappy" as the compounder when it is not.
What it means for the offer
Every other page in this collection describes a company invoking a brand. This one describes a company invoking the regulator: the listings FDA quoted sent shoppers to FDA's own information about Wegovy, Saxenda and Zepbound from beside a compounded product FDA has not reviewed. That is the most persuasive citation a page can offer and, in FDA's account, the least applicable — the linked material describes the approved drug, not the one in the cart. It is a genuinely useful thing to carry into any price comparison: a link to an authoritative source is only as relevant as the product it is attached to, and a footnote pointing at the FDA does not convert the item above it into an FDA-reviewed product.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Zappy's website], in December 2025, and has observed that your website offers compounded drug products, including semaglutide, tirzepatide, and liraglutide drug products.
The compounded semaglutide, tirzepatide, and liraglutide products displayed on your website identify “Zappy” on the pictured label, suggesting Zappy is the compounder of those drugs when in fact it is not.
“Semaglutide (Active Pharmaceutical Ingredient in Wegovy®)See Wegovy FDA Information” [sic] “Liraglutide (Active Pharmaceutical Ingredient in Saxenda®)See Saxenda FDA Information” [sic] “Tirzepatide (Active Pharmaceutical Ingredient in Zepbound®)See Zepbound FDA Information” [sic]
“a proven medication” “Clinically studied and shown to deliver powerful results when combined with healthy habits.”
Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
Zappy's website returned a live storefront when we checked in August 2026, advertising a program with a published entry price and listing compounded semaglutide and tirzepatide alongside branded Wegovy and Zepbound options.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Zeuss
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
Alone among the letters we cover, one of the cited claims is about testing: "each batch rigorously tested for efficacy and safety." FDA did not examine any batch — it said the claim, together with "Proven Weight Loss" and "GLP-1 is a class of medication that mimic naturally produced hormone in a body. It is FDA approved and clinically proven to work treatment for weight loss," implies the products "have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not." FDA separately noted the pictured vial identifies "Zeuss" as though Zeuss were the compounder, "when in fact it is not."
What it means for the offer
Read the testing claim carefully, in both directions. "Each batch rigorously tested" is the sentence that answers the question most shoppers actually have about a cheap compounded vial — who checked this? — and FDA's objection is that the sentence sits next to an assertion of FDA approval that the product does not have. What the letter does not do is check any batch or report a defect, so nobody should read it as a finding about what was in the vials. The useful takeaway is about who is making the promise: batch testing by a seller is a claim by the seller, and the compounder that actually made the product was, on FDA's account, someone other than the name on the label. If testing matters to you at the price you are paying, the question worth asking is which facility performed it and what was measured.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Zeuss' website], in December 2025, and has observed that your website offers compounded drug products, including tirzepatide drug products.
The compounded tirzepatide products displayed on your website identify “Zeuss” on the pictured label, suggesting Zeuss is the compounder of those drugs when in fact it is not.
“each batch rigorously tested for efficacy and safety”
Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
Zeuss' website returned a live storefront when we checked in August 2026, organized into men's and women's programs covering body, skin, hair, testosterone and hormone therapy, with a refund promise if a physician does not prescribe. We did not review every page, so we cannot say whether the tirzepatide product named in the letter is still offered.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.